Divalproex for Managing Aggression and Irritability in Children with Autism Spectrum Disorder: A Systematic Review.

This review looked at whether divalproex (a seizure medication sometimes used for mood problems) helps with aggression and irritability in autistic children. Researchers found 10 studies to review. When given through an IV in hospitals, divalproex quickly reduced aggressive behavior. However, when taken as pills for ongoing problems, results were mixed and inconsistent.

Side effects included weight gain, drowsiness, and sometimes increased behavioral problems. The medication may help during crisis situations but isn't clearly helpful for long-term daily use.

This systematic review examined divalproex (an anticonvulsant and mood stabilizer) for managing aggression and irritability in children with autism spectrum disorder. The review included 10 studies: 3 randomized controlled trials, 1 open-label trial, and 6 case reports. Intravenous divalproex showed rapid reductions in aggression, suggesting potential for acute crisis intervention. However, oral divalproex produced inconsistent results for ongoing management of chronic aggression and irritability.

Common adverse effects included weight gain, sedation, and behavioral activation, with increased toxicity risks when combined with other medications. The authors concluded that while divalproex may have value for acute aggression management, its role in chronic treatment remains unclear due to inconsistent outcomes and significant side effects.

Divalproex may be considered for acute aggression management in hospital settings but has unclear benefits for chronic use. Regular serum monitoring is essential. Clinicians should weigh potential benefits against notable side effects and consider alternative treatments for long-term management of aggression and irritability in autistic children.

Small number of included studies with limited sample sizes. Six of ten studies were case reports, providing weaker evidence. Inconsistent outcomes across studies limit generalizability. No information provided about total sample sizes across studies.

Aggression and irritability are common challenges in children with autism spectrum disorder (ASD), often requiring pharmacological management. Divalproex, an anticonvulsant and mood stabilizer, is used off-label for these symptoms, but its effectiveness remains unclear. This systematic review evaluates the efficacy and safety of divalproex in managing aggression and irritability in children with ASD.A systematic review was conducted following PRISMA guidelines, registered with PROSPERO (CRD420251029754). Searches were performed in PubMed, Embase, PsycINFO, and Web of Science, identifying studies involving children with ASD treated with divalproex, valproic acid, or valproate sodium.

Data were extracted on study design, sample size, intervention details, outcomes, and adverse effects.Ten studies met inclusion criteria, comprising three randomized controlled trials, one open-label trial, and six case reports. Intravenous (IV) divalproex demonstrated rapid reductions in aggression, suggesting potential for acute stabilization. However, oral divalproex produced inconsistent results for chronic aggression and irritability. Adverse effects included weight gain, sedation, and behavioral activation, with toxicity risks in polypharmacy settings.Divalproex may offer value for acute management of aggression in children with ASD when administered intravenously.

Its role in chronic management is less clear, with inconsistent outcomes and notable side effects. Clinicians should prioritize regular serum monitoring and consider alternative options for chronic use. Further research is needed to clarify its clinical role, particularly in diverse patient populations.